Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transfusion-dependent Thalassemia
Conditions
Transfusion-dependent Thalassemia, Non-transfusion-dependent Thalassemia
Trial Timeline
Jul 27, 2017 → Mar 11, 2021
NCT ID
NCT02993224About Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT)
Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT) is a phase 2 stage product being developed by Novartis for Transfusion-dependent Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02993224. Target conditions include Transfusion-dependent Thalassemia, Non-transfusion-dependent Thalassemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02993224 | Phase 2 | Completed |
Competing Products
8 competing products in Transfusion-dependent Thalassemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Deferasirox | Novartis | Phase 3 | 77 |
| Deferasirox + Deferoxamine (DFO) | Novartis | Phase 2 | 52 |
| Deferasirox granule formulation + Deferasirox DT formulation | Novartis | Phase 2 | 52 |
| Deferoxamine + Deferasirox | Novartis | Approved | 85 |
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 72 |
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 72 |
| SLN124 + Placebo | Silence Therapeutics | Phase 1 | 25 |
| SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo | Silence Therapeutics | Phase 1 | 25 |